Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on International Tech Times.
Press releases published on May 7, 2025
Spectral Medical Announces Non-Dilutive Financing of Up to $10 Million with Vantive
GlobeNewswire
·
May 7, 2025
• Non-Dilutive Financing • Up to US$10 Million Promissory Note Provided by Vantive • If Fully Drawn, Promissory Note is Expected to Fully Fund Spectral to PMX Commercialization • Company to host Corporate Update Call on May 15, 2025 TORONTO, May 07, …
Northland Power Announces Commercial Operations at Oneida Energy Storage Project – Canada’s Largest Battery Storage Facility Delivered Ahead of Schedule and Below Budget
GlobeNewswire
·
May 7, 2025
Oneida Energy Storage Project, April 2025 TORONTO, May 07, 2025 (GLOBE NEWSWIRE) -- Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) is pleased to announce that the Oneida Energy Storage Project (“Oneida”) has successfully commenced …
GDS to Report First Quarter 2025 Financial Results Before the Open of the U.S. Market on May 20, 2025
GlobeNewswire
·
May 7, 2025
SHANGHAI, China, May 07, 2025 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced that it will report its …
Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies
GlobeNewswire
·
May 7, 2025
MILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading Biotech Manufacturing Organization (BMO) …
Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City
GlobeNewswire
·
May 7, 2025
TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation …
Immunocore reports first quarter financial results and provides a business update
GlobeNewswire
·
May 7, 2025
Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On …
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved
GlobeNewswire
·
May 7, 2025
For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues …
Climb Channel Solutions Partners with Smartsheet for Industry-Leading Collaborative Work Management
GlobeNewswire
·
May 7, 2025
EATONTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB) is excited to be adding Smartsheet, the AI-enhanced …
Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025
GlobeNewswire
·
May 7, 2025
REHOVOT, Israel, and HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader …
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
GlobeNewswire
·
May 7, 2025
Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen When …
Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients
GlobeNewswire
·
May 7, 2025
- Patients treated with VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel standard-of-care (SoC) chemotherapy had increased overall survival, progression free survival, and duration of response compared to patients treated with gemcitabine …
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
GlobeNewswire
·
May 7, 2025
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas, NV on Wednesday, May 14, 2025, at 8:00 …
Dayforce Reports First Quarter 2025 Results¹
GlobeNewswire
·
May 7, 2025
Dayforce® recurring revenue, excluding float, of $323 million, up 14%, or 16% on a constant currency basis Total revenue of $482 million, up 12%, and excluding float, up 15%, or 17% on a constant currency basis Net cash provided by operating activities of …
Amarin Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
-- First Quarter 2025 Performance Reflects Contribution from Multiple Revenue Streams Across Geographies, Efforts to Support Strong Balance Sheet and Continued Strategic Execution to Maximize Global Value of VASCEPA®/VAZKEPA® -- -- Nasdaq Listing …
HydroGraph CEO to Speak at Prestigious Hemispheric Security Conference and Lead May Investor Roundtable
GlobeNewswire
·
May 7, 2025
VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- HydroGraph Clean Power Inc. (CSE: HG / OTCQB: HGRAF), a leading producer of ultra-pure graphene and advanced nanomaterials, today announced two key events underscoring the Company’s growing role …
KVH Industries Reports First Quarter 2025 Results
GlobeNewswire
·
May 7, 2025
MIDDLETOWN, R.I., May 07, 2025 (GLOBE NEWSWIRE) -- KVH Industries, Inc. (Nasdaq: KVHI), reported financial results for the quarter ended March 31, 2025 today. The company will hold a conference call to discuss these results at 9:00 a.m. ET today, which can …
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 7, 2025
Updated Cemsidomide Multiple Myeloma Data Further Demonstrate Compelling Response Rates at Multiple Doses and Potential for Best-in-Class Profile; 50% ORR Observed at the Highest Dose Level of 100 µg, Including One Patient With a Minimal Residual Disease …
Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference
GlobeNewswire
·
May 7, 2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the …
Castle Biosciences Celebrates Skin Cancer Awareness Month
GlobeNewswire
·
May 7, 2025
The Company continues its ongoing partnerships with IMPACT Melanoma, AIM at Melanoma and Melanoma Research Foundation to drive education and awareness throughout May Castle highlights cancer journey of melanoma survivor and advocate, Leah Adams A Media …
Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance
GlobeNewswire
·
May 7, 2025
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase …